Charles River Laboratories International (CRL) ROIC: History & Chart

Name: Charles River Laboratories International, Inc. (CRL) Return on Invested Capital (ROIC) — historical time series
Creator: TGMCharts

Compare

Charles River Laboratories International, Inc.(CRL)

Medical - Diagnostics & Research · Wilmington, MA

$280.76+0.00 (+0.00%)

Delayed quote: Sep 8, 2026, 4:00 PM EDT

Compare

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA

19,000 employees

www.criver.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Birgit Girshick

View full financials

CRL Return on Invested Capital (ROIC) Metrics

RETURN ON INVESTED CAPITAL (ROIC)

7.72%

RETURN ON INVESTED CAPITAL (ROIC) AVG TTM

5.21%

RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y

5.47%

RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y

7.51%

RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y

7.31%

RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y

7.77%

RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y

7.49%

CURRENT VS TTM AVG

+48.19%

CURRENT VS 3Y AVG

+41.12%

CURRENT VS 5Y AVG

+2.81%

CURRENT VS 10Y AVG

+5.65%

CURRENT VS 15Y AVG

-0.60%

CURRENT VS 20Y AVG

+3.09%

SECTOR MEDIAN · HEALTHCARE

8.75%

median of 90 covered companies

CURRENT VS SECTOR MEDIAN

-11.73%

vs the sector median at left

NAME	MARKET CAP	RETURN ON INVESTED CAPITAL (ROIC)	TTM	3Y	5Y
Charles River Laboratories International, Inc. (CRL)	$13.52B	7.72%	5.21%	5.47%	7.51%
The Cooper Companies, Inc. (COO)vs ›	$13.20B	2.52%	4.09%	3.90%	4.30%
Revvity, Inc. (RVTY)vs ›	$14.18B	2.91%	2.97%	3.43%	5.52%
Baxter International Inc. (BAX)vs ›	$12.85B	-1.61%	-0.86%	-2.74%	0.22%
Penumbra, Inc. (PEN)vs ›	$12.58B	8.48%	7.10%	4.92%	2.27%
Exelixis, Inc. (EXEL)vs ›	$14.50B	37.87%	23.96%	17.78%	13.78%
Encompass Health Corporation (EHC)vs ›	$11.95B	13.42%	12.59%	14.85%	11.33%
DaVita Inc. (DVA)vs ›	$11.56B	11.18%	11.30%	9.75%	9.57%
Solventum Corporation (SOLV)vs ›	$15.60B	15.85%	12.30%	11.68%	11.64%
Bio-Techne Corporation (TECH)vs ›	$11.32B	7.86%	5.36%	7.03%	8.47%

NAME

MARKET CAP

RETURN ON INVESTED CAPITAL (ROIC)

TTM

Charles River Laboratories International, Inc. (CRL)

$13.52B

7.72%

5.21%

5.47%

7.51%

The Cooper Companies, Inc. (COO)vs ›

$13.20B

2.52%

4.09%

3.90%

4.30%

Revvity, Inc. (RVTY)vs ›

$14.18B

2.91%

2.97%

3.43%

5.52%

Baxter International Inc. (BAX)vs ›

$12.85B

-1.61%

-0.86%

-2.74%

0.22%

Penumbra, Inc. (PEN)vs ›

$12.58B

8.48%

7.10%

4.92%

2.27%

Exelixis, Inc. (EXEL)vs ›

$14.50B

37.87%

23.96%

17.78%

13.78%

Encompass Health Corporation (EHC)vs ›

$11.95B

13.42%

12.59%

14.85%

11.33%

DaVita Inc. (DVA)vs ›

$11.56B

11.18%

11.30%

9.75%

9.57%

Solventum Corporation (SOLV)vs ›

$15.60B

15.85%

12.30%

11.68%

11.64%

Bio-Techne Corporation (TECH)vs ›

$11.32B

7.86%

5.36%

7.03%

8.47%

Return on Invested Capital (ROIC) Formula & Definition

ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)

Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.

Return on Invested Capital (ROIC) FAQ

What is the return on invested capital (ROIC) for Charles River Laboratories International, Inc. (CRL)?

The return on invested capital (ROIC) for CRL stock is 7.72%.

Is Charles River Laboratories International, Inc.'s return on invested capital (ROIC) high or low?

The return on invested capital (ROIC) of 7.72% is in line with its 5-year average of 7.51%, near the high end of its 5-year range (1.48%–8.53%).

What is the TTM average return on invested capital (ROIC) for Charles River Laboratories International, Inc. (CRL)?

The TTM average return on invested capital (ROIC) for CRL stock is 5.21%.

What is the 3Y average return on invested capital (ROIC) for Charles River Laboratories International, Inc. (CRL)?

The 3Y average return on invested capital (ROIC) for CRL stock is 5.47%.

What is the 5Y average return on invested capital (ROIC) for Charles River Laboratories International, Inc. (CRL)?

The 5Y average return on invested capital (ROIC) for CRL stock is 7.51%.

What is the 10Y average return on invested capital (ROIC) for Charles River Laboratories International, Inc. (CRL)?

The 10Y average return on invested capital (ROIC) for CRL stock is 7.31%.

What is the 15Y average return on invested capital (ROIC) for Charles River Laboratories International, Inc. (CRL)?

The 15Y average return on invested capital (ROIC) for CRL stock is 7.77%.

What is the 20Y average return on invested capital (ROIC) for Charles River Laboratories International, Inc. (CRL)?

The 20Y average return on invested capital (ROIC) for CRL stock is 7.49%.

DATE	RETURN ON INVESTED CAPITAL (ROIC)
2026-06-27	7.72%
2026-03-28	7.14%
2025-12-27	7.06%
2025-09-27	2.20%
2025-06-28	1.92%
2025-03-29	1.48%
2024-12-31	1.91%
2024-09-28	6.23%
2024-06-29	6.62%
2024-03-30	6.56%
2023-12-31	7.14%
2023-09-30	7.63%
2023-07-01	7.47%
2023-04-01	7.77%
2022-12-31	7.91%
2022-09-24	8.48%
2022-06-25	8.53%
2022-03-26	8.28%
2021-12-31	8.17%
2021-09-25	7.40%
2021-06-26	7.21%
2021-03-27	7.63%
2020-12-31	7.53%
2020-09-26	7.32%
2020-06-27	6.99%
2020-03-28	7.01%
2019-12-31	7.30%
2019-09-28	7.49%
2019-06-29	6.76%
2019-03-30	7.84%
2018-12-31	8.03%
2018-09-29	4.88%
2018-06-30	4.58%
2018-03-31	6.06%
2017-12-31	6.35%
2017-09-30	8.15%
2017-07-01	7.98%
2017-04-01	7.25%
2016-12-31	7.20%
2016-09-24	6.59%
2016-06-25	6.29%
2016-03-26	8.70%
2015-12-31	9.05%
2015-09-26	8.92%
2015-06-27	9.17%
2015-03-28	8.71%
2014-12-31	8.02%
2014-09-27	7.65%
2014-06-28	7.24%
2014-03-29	7.93%
2013-12-31	8.13%
2013-09-28	8.72%
2013-06-29	8.81%
2013-03-30	9.15%
2012-12-31	9.43%
2012-09-29	9.85%
2012-06-30	9.88%
2012-03-31	10.19%
2011-12-31	11.19%
2011-09-24	-16.55%
2011-06-25	-17.45%
2011-03-26	-18.44%
2010-12-31	-19.59%
2010-09-25	2.91%
2010-06-26	5.21%
2010-03-27	5.87%
2009-12-31	6.15%
2009-09-26	-26.16%
2009-06-27	-25.64%
2009-03-28	-25.69%
2008-12-31	-23.75%
2008-09-27	6.99%
2008-06-28	7.03%
2008-03-29	6.70%
2007-12-31	6.53%
2007-09-29	6.39%
2007-06-30	6.08%
2007-03-31	6.10%
2006-12-31	1.42%
2006-09-30	1.23%
2006-07-01	1.12%
2006-04-01	1.26%
2005-12-31	7.14%
2005-09-24	5.39%
2005-06-25	5.10%
2005-03-26	4.62%
2004-12-31	4.07%
2004-09-25	12.35%
2004-06-26	12.04%
2004-03-27	11.62%
2003-12-31	12.44%
2003-09-27	12.60%
2003-06-28	12.96%

DATE

RETURN ON INVESTED CAPITAL (ROIC)

2026-06-27

7.72%

2026-03-28

7.14%

2025-12-27

7.06%

2025-09-27

2.20%

2025-06-28

1.92%

2025-03-29

1.48%

2024-12-31

1.91%

2024-09-28

6.23%

2024-06-29

6.62%

2024-03-30

6.56%

2023-12-31

7.14%

2023-09-30

7.63%

2023-07-01

7.47%

2023-04-01

7.77%

2022-12-31

7.91%

2022-09-24

8.48%

2022-06-25

8.53%

2022-03-26

8.28%

2021-12-31

8.17%

2021-09-25

7.40%

2021-06-26

7.21%

2021-03-27

7.63%

2020-12-31

7.53%

2020-09-26

7.32%

2020-06-27

6.99%

2020-03-28

7.01%

2019-12-31

7.30%

2019-09-28

7.49%

2019-06-29

6.76%

2019-03-30

7.84%

2018-12-31

8.03%

2018-09-29

4.88%

2018-06-30

4.58%

2018-03-31

6.06%

2017-12-31

6.35%

2017-09-30

8.15%

2017-07-01

7.98%

2017-04-01

7.25%

2016-12-31

7.20%

2016-09-24

6.59%

2016-06-25

6.29%

2016-03-26

8.70%

2015-12-31

9.05%

2015-09-26

8.92%

2015-06-27

9.17%

2015-03-28

8.71%

2014-12-31

8.02%

2014-09-27

7.65%

2014-06-28

7.24%

2014-03-29

7.93%

2013-12-31

8.13%

2013-09-28

8.72%

2013-06-29

8.81%

2013-03-30

9.15%

2012-12-31

9.43%

2012-09-29

9.85%

2012-06-30

9.88%

2012-03-31

10.19%

2011-12-31

11.19%

2011-09-24

-16.55%

2011-06-25

-17.45%

2011-03-26

-18.44%

2010-12-31

-19.59%

2010-09-25

2.91%

2010-06-26

5.21%

2010-03-27

5.87%

2009-12-31

6.15%

2009-09-26

-26.16%

2009-06-27

-25.64%

2009-03-28

-25.69%

2008-12-31

-23.75%

2008-09-27

6.99%

2008-06-28

7.03%

2008-03-29

6.70%

2007-12-31

6.53%

2007-09-29

6.39%

2007-06-30

6.08%

2007-03-31

6.10%

2006-12-31

1.42%

2006-09-30

1.23%

2006-07-01

1.12%

2006-04-01

1.26%

2005-12-31

7.14%

2005-09-24

5.39%

2005-06-25

5.10%

2005-03-26

4.62%

2004-12-31

4.07%

2004-09-25

12.35%

2004-06-26

12.04%

2004-03-27

11.62%

2003-12-31

12.44%

2003-09-27

12.60%

2003-06-28

12.96%

Return on Invested Capital (ROIC): 7.72%

CRL Return on Invested Capital (ROIC)

CRL Average Return on Invested Capital (ROIC) Chart

CRL Current vs Average Return on Invested Capital (ROIC) Chart

CRL Return on Invested Capital (ROIC) Metrics

CRL Competitors' Return on Invested Capital (ROIC)

Capital Efficiency

Return on Invested Capital (ROIC) Formula & Definition

Return on Invested Capital (ROIC) FAQ

CRL Return on Invested Capital (ROIC) History

Related Metrics